Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments
Gliomas are one of the most lethal types of cancers accounting for ∼80% of all central nervous system (CNS) primary malignancies. Among gliomas, glioblastomas (GBM) are the most aggressive, characterized by a median patient survival of fewer than 15 months. Recent molecular characterization studies...
Auteurs principaux: | Mahmoud S. Alghamri, Brandon L. McClellan, Carson S. Hartlage, Santiago Haase, Syed Mohd Faisal, Rohit Thalla, Ali Dabaja, Kaushik Banerjee, Stephen V. Carney, Anzar A. Mujeeb, Michael R. Olin, James J. Moon, Anna Schwendeman, Pedro R. Lowenstein, Maria G. Castro |
---|---|
Format: | Article |
Langue: | English |
Publié: |
Frontiers Media S.A.
2021-05-01
|
Collection: | Frontiers in Pharmacology |
Sujets: | |
Accès en ligne: | https://www.frontiersin.org/articles/10.3389/fphar.2021.680021/full |
Documents similaires
-
Murine brain tumor microenvironment immunophenotyping using mass cytometry
par: Brandon L. McClellan, et autres
Publié: (2022-06-01) -
Impact of epigenetic reprogramming on antitumor immune responses in glioma
par: Brandon L. McClellan, et autres
Publié: (2023-01-01) -
Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies
par: Maria B. Garcia-Fabiani, et autres
Publié: (2021-06-01) -
Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment
par: Andrea Franson, et autres
Publié: (2022-09-01) -
H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models
par: Santiago Haase, et autres
Publié: (2022-11-01)